APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer’s mice via cyclophilin A independently of amyloid-β

Axel Montagne,Angeliki M. Nikolakopoulou,Mikko T. Huuskonen,Abhay P. Sagare,Erica J. Lawson,Divna Lazic,Sanket V. Rege,Alexandra Grond,Edward Zuniga,Samuel R. Barnes,Jacob Prince,Meghana Sagare,Ching-Ju Hsu,Mary J. LaDu,Russell E. Jacobs,Berislav V. Zlokovic
DOI: https://doi.org/10.1038/s43587-021-00073-z
2021-06-01
Nature Aging
Abstract:Apolipoprotein E4 (<i>APOE4</i>), the main susceptibility gene for Alzheimer's disease (AD), leads to vascular dysfunction, amyloid-β pathology, neurodegeneration and dementia. How these different pathologies contribute to advanced-stage AD remains unclear. Using aged APOE knock-in mice crossed with <i>5xFAD</i> mice, we show that, compared to APOE3, APOE4 accelerates blood–brain barrier (BBB) breakdown, loss of cerebral blood flow, neuronal loss and behavioral deficits independently of amyloid-β. BBB breakdown was associated with activation of the cyclophilin A-matrix metalloproteinase-9 BBB-degrading pathway in pericytes. Suppression of this pathway improved BBB integrity and prevented further neuronal loss and behavioral deficits in APOE4;5FAD mice while having no effect on amyloid-β pathology. Thus, APOE4 accelerates advanced-stage BBB breakdown and neurodegeneration in Alzheimer's mice via the cyclophilin A pathway in pericytes independently of amyloid-β, which has implication for the pathogenesis and treatment of vascular and neurodegenerative disorder in AD.
What problem does this paper attempt to address?